Steve brings more than 25 years of healthcare experience to MannKind, including leading financial operations at biopharmaceutical and medical technology companies. Since July 2017, he has guided MannKind’s financial strategy, setting us up for financial success so that we can help others truly thrive.
With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza® (insulin human) Inhalation Powder will be affected by the coronavirus.
We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin.
Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. Afrezza is still readily available in U.S. pharmacies, and if needed, pharmacies can order additional supplies from wholesalers with expected delivery within 1-2 days. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza.